Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 11:08 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2761–2784 of 26,682 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: CTRL Clear all

Conditions: Diabetes Mellitus
Interventions: PPM-204; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 11
States / cities: Artesia, California • Los Angeles, California • Chipley, Florida + 8 more

Conditions: Healthy Volunteers
Interventions: TAK-279, TAK-279 Placebo, Moxifloxacin, Moxifloxacin Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Adenomyosis
Interventions: Epelsiban, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 55 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 13
States / cities: Washington D.C., District of Columbia • West Palm Beach, Florida • Champaign, Illinois + 10 more

Conditions: Creutzfeldt-Jakob Disease
Interventions: Quinacrine, Placebo; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2012
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Clinically Significant Portal Hypertension
Interventions: Placebo, Sorafenib; Drug
Lead sponsor: Yale University; Other
Eligibility: 20 Years to 75 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 6
States / cities: New Haven, Connecticut • West Haven, Connecticut • Boston, Massachusetts + 3 more

Conditions: HIV Infections
Interventions: rgp120/HIV-1MN; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 1999
U.S. locations: 3
States / cities: Birmingham, Alabama • Rochester, New York • Seattle, Washington

Conditions: Parkinson's Disease Psychosis
Interventions: Pimavanserin tartrate (ACP-103), Placebo; Drug
Lead sponsor: ACADIA Pharmaceuticals Inc.; Industry
Eligibility: 40 Years and older
Enrollment: 298 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 36
States / cities: Gilbert, Arizona • Phoenix, Arizona • Berkeley, California + 33 more

Conditions: Prevention From Norovirus Infection
Interventions: Norovirus Bivalent Vaccine, Saline Comparator; Biological
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 132 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 5
States / cities: Atlanta, Georgia • Baltimore, Maryland • Rochester, New York + 2 more

Conditions: Diabetic Foot Ulcers (DFUs), Diabetic Foot, Chronic Wounds
Interventions: Miro3D Wound Matrix, Standard of Care; Device · Other
Lead sponsor: Reprise Biomedical, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 14
States / cities: Phoenix, Arizona • Coconut Creek, Florida • Coral Gables, Florida + 9 more

Conditions: Lupus Nephritis
Interventions: Etanercept, Lupus Treatment- Standard of Care, Placebo; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 75 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 6
States / cities: Birmingham, Alabama • San Francisco, California • Aurora, Colorado + 3 more

Conditions: Stroke
Interventions: 60-min isometric MyCI training, 90-min isometric MyCI training, 90-min movement MyCI training; Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Respiratory Distress Syndrome in Premature Infant
Interventions: AeroFact, nCPAP; Drug · Other
Lead sponsor: Aerogen Pharma Limited; Industry
Eligibility: 26 Weeks to 31 Weeks
Enrollment: 261 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 37
States / cities: Little Rock, Arkansas • Berkeley, California • Orange, California + 27 more

Conditions: Hidradenitis Suppurativa (HS)
Interventions: Povorcitinib, Placebo; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 619 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 38
States / cities: Scottsdale, Arizona • Arkansas City, Arkansas • Fayetteville, Arkansas + 33 more

Conditions: Psoriasis Vulgaris, Topical Administration
Interventions: Total coumarin (TC) cream, Vehicle; Drug
Lead sponsor: Psoriasis Research Institute of Guangzhou; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 2
States / cities: New York, New York • Seattle, Washington

Conditions: Sleep Disturbances in Perimenopause
Interventions: Brahmi-Gotukola oil padabhyanga, Sesame oil Padabhyanga; Behavioral
Lead sponsor: Saipriya Gowrishankar; Other
Eligibility: 40 Years to 55 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Fairfield, Iowa

Conditions: Opioid Use Disorder
Interventions: Naltrexone, Placebo, Buprenorphine; Drug
Lead sponsor: Alkermes, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 9
States / cities: Lauderhill, Florida • Oakland Park, Florida • Winfield, Illinois + 6 more

Conditions: This Study Will Evaluate Whether TXA Reduces Pain
Interventions: Tranexamic acid, placebo; Drug · Other
Lead sponsor: St. Louis Joint Replacement Institute; Other
Eligibility: Not listed
Enrollment: 165 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Bridgeton, Missouri

Conditions: Cystic Fibrosis
Interventions: VX-659, TEZ/IVA, IVA, Placebo (matched to VX-659/TEZ/IVA), TEZ, VX-561, Placebo (matched to VX-659/TEZ/VX-561); Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 25
States / cities: New Haven, Connecticut • Miami, Florida • Morton Grove, Illinois + 22 more

Conditions: Rheumatoid Arthritis
Interventions: Placebo for VIB4920, VIB4920 with TNFi, VIB4920 without TNFi; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 5
States / cities: San Francisco, California • Aurora, Colorado • Boston, Massachusetts + 2 more

Conditions: Germ Cell Tumors
Interventions: Aprepitant, Placebo; Drug
Lead sponsor: Hoosier Cancer Research Network; Other
Eligibility: 15 Years and older · Male only
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 6
States / cities: Indianapolis, Indiana • Muncie, Indiana • St Louis, Missouri + 3 more

Conditions: Eczema, Atopic Dermatitis
Interventions: Amlitelimab, Placebo; Drug
Lead sponsor: Kymab Limited; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 390 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 20
States / cities: Fremont, California • Sacramento, California • Boca Raton, Florida + 16 more

Conditions: Diabetic Peripheral Neuropathic Pain
Interventions: LY3556050, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 35
States / cities: Chandler, Arizona • Glendale, Arizona • Tempe, Arizona + 28 more

Conditions: Pulmonary Disease, Chronic Obstructive, Exercise
Interventions: tiotropium 18 mcg, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years and older
Enrollment: 519 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 21
States / cities: Jasper, Alabama • Phoenix, Arizona • Los Angeles, California + 18 more

Conditions: Type 2 Diabetes
Interventions: Saxagliptin, Placebo, Metformin (blinded), Metformin (open-label); Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 3
States / cities: San Diego, California • Baton Rouge, Louisiana • San Antonio, Texas

Search by objective public record fields.

Study Evaluating PPM-204 In Subjects With Type 2 Diabetes

A Study of TAK-279 in Healthy Adults on the Effect on ECG Measurements

Placebo-controlled Proof of Concept Study of Epelsiban in Women With Adenomyosis

CJD (Creutzfeldt-Jakob Disease) Quinacrine Study

The Effect of Sorafenib on Portal Pressure

A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of Low Dose MN rsgp120/HIV-1 (Genentech) in Combination With QS21 Adjuvant or Alum in Healthy Adults

A Study of the Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis

Norovirus Bivalent-Vaccine Efficacy Study

Miro3D Wound Matrix for Treatment of Diabetic Foot Ulcers

Etanercept for the Treatment of Lupus Nephritis

Myoelectric Computer Interface to Reduce Muscle Co-activation After Stroke

A Dose-Ranging Study to Determine the Efficacy, Safety and Tolerability of AeroFact

A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa (HS)

Efficacy and Safety of a Botanical Total Coumarin (TC) Cream in Treating Patients With Psoriasis Vulgaris (PLANTCOAT-IIb Trial)

A Study Comparing the Effects of Two Types of Natural Oils Used in a Bedtime Foot Massage Routine on Sleep and Emotional Well-Being in Perimenopausal Women.

Evaluating Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Transitioning From Buprenorphine Maintenance Prior to First Dose of VIVITROL

Effect of Tranexamic Acid (TXA) Administered Prior to Shoulder Arthroscopy on Postoperative Pain Medication Usage: A Randomized Controlled Trial

A Study Evaluating the Safety and Efficacy of VX-659 Combination Therapy in Subjects With Cystic Fibrosis

CD40L Antagonism in Rheumatoid Arthritis (RA)

Aprepitant + a 5HT3 + Dexamethasone in Patients With Germ Cell Tumors

Study Testing Response Effect of KY1005 Against Moderate-to-Severe Atopic Dermatitis, The STREAM-AD Study

Chronic Pain Master Protocol (CPMP): A Study of LY3556050 in Participants With Diabetic Peripheral Neuropathic Pain

Tiotropium In Exercise

A Study Assessing Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise